Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment
This study investigated the spontaneous reversibility of bone loss caused by gonadotropin-releasing hormone analog treatment, finding that bone mineral density partially recovered after cessation of the treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (24)
- Bone mass in endometriosis patients treated with GnRH agonist implant or danazol via openalex
- Bone mineral density of the lumbar spine in endometriosis subjects compared to an age-similar control population via openalex
- Changing concepts of medical treatment of endometriosis via openalex
- Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain via openalex
- Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy via openalex
- Goserelin (Zoladex ) depot in the treatment of endometriosis via openalex
- Hormone treatment of endometriosis: the estrogen threshold hypothesis via openalex
- Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? via openalex
- Nafarelin therapy in endometriosis: long-term effects on bone mineral density via openalex
- Reduced bone mass in reproductive-aged women with endometriosis via openalex
- Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma via openalex
- W2467395168 via openalex
- W2472762831 via openalex
- W6714902491 via openalex
- W1512318310 via openalex
- W1984155944 via openalex
- W1999502490 via openalex
- W2010663321 via openalex
- W2055260481 via openalex
- W2078632549 via openalex
- W2109034857 via openalex
- W2128241866 via openalex
- W2153895111 via openalex
- W2287757320 via openalex
Cited by (26)
- The effectiveness of the gonadotropin-releasing analogues in managing adenomyosis and its related symptoms 2026
- Pharmacokinetic considerations for gonadotropin-releasing hormone agonists and antagonists to treat endometriosis 2025
- The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis 2022
- Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis 2022
- Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data 2019
- Repeated two cycles of ulipristal acetate treatment improve the quality of life in premenopausal women with heavy menstrual bleeding dependent on uterine myomas, without impairment of bone health 2019
- Emerging therapy for endometriosis 2015
- An update on the pharmacological management of endometriosis 2013
- Catamenial pneumothorax: a case report and review of the literature 2008
- GnRH analogs: options for endometriosis-associated pain treatment 2006
- Long-term fracture risk among women with proven endometriosis 2006
- Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial 2006
- Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial 2006
- Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain 2006
- Painful menstruation 2005
- Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate 2005
- Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus 2005
- Prolonged GnRH Agonist and Add-Back Therapy for Symptomatic Endometriosis 2002
- Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone 2002
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up 2000
- Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial 2000
- A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis 2000
- Endometriosis: an overview of the disease and its treatment 2000
- Medical Treatment of Endometriosis-Associated Pain 1999
- Women of reproductive age with endometriosis are not osteopenic 1998
- GnRH agonists and add-back therapy: is there a perfect combination? 1998
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00